当前位置: 首页 >> 检索结果
781. Feasibility of Shockwave Coronary Intravascular Lithotripsy for the Treatment of Calcified Coronary Stenoses.
作者: Todd J Brinton.;Ziad A Ali.;Jonathan M Hill.;Ian T Meredith.;Akiko Maehara.;Uday Illindala.;Alexandra Lansky.;Matthias Götberg.;Nicolas M Van Mieghem.;Robert Whitbourn.;Jean Fajadet.;Carlo Di Mario.
来源: Circulation. 2019年139卷6期834-836页 782. Predictive Model for High-Risk Coronary Artery Disease.
作者: James J Jang.;Manjushri Bhapkar.;Adrian Coles.;Sreekanth Vemulapalli.;Christopher B Fordyce.;Kerry L Lee.;James E Udelson.;Udo Hoffmann.;Jean-Claude Tardif.;W Schuyler Jones.;Daniel B Mark.;Vincent L Sorrell.;Andrey Espinoza.;Pamela S Douglas.;Manesh R Patel.; .
来源: Circ Cardiovasc Imaging. 2019年12卷2期e007940页
Patients with high-risk coronary artery disease (CAD) may be difficult to identify.
783. Association of International Normalized Ratio Stability and Bleeding Outcomes Among Atrial Fibrillation Patients Undergoing Percutaneous Coronary Intervention.
作者: Mathieu Kerneis.;Megan K Yee.;Roxana Mehran.;Tarek Nafee.;Christoph Bode.;Jonathan L Halperin.;Eric D Peterson.;Freek W A Verheugt.;Peter Wildgoose.;Martin van Eickels.;Gregory Y H Lip.;Marc Cohen.;Keith A A Fox.;C Michael Gibson.
来源: Circ Cardiovasc Interv. 2019年12卷2期e007124页
Among atrial fibrillation patients undergoing percutaneous coronary intervention enrolled in PIONEER AF-PCI (An Open-Label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention), it is unclear if the observed reduction in bleeding events with rivaroxaban regimens is consistent across a range of the international normalized ratio (INR) among subjects administrated Vitamin K antagonist (VKA)-triple therapy. This analysis compares the occurrence of clinically significant bleeding between rivaroxaban and VKA strategies, according to INR stability of subjects administrated VKA.
784. Use, Temporal Trends, and Outcomes of Endovascular Therapy After Interhospital Transfer in the United States.
作者: Shreyansh Shah.;Ying Xian.;Shubin Sheng.;Kori S Zachrison.;Jeffrey L Saver.;Kevin N Sheth.;Gregg C Fonarow.;Lee H Schwamm.;Eric E Smith.
来源: Circulation. 2019年139卷13期1568-1577页
The use of endovascular therapy (EVT) in patients with acute ischemic stroke who have large vessel occlusion has rapidly increased in the United States following pivotal trials demonstrating its benefit. Information about the contribution of interhospital transfer in improving access to EVT will help organize regional systems of stroke care.
785. Stroke Outcomes in the COMPASS Trial.
作者: Mukul Sharma.;Robert G Hart.;Stuart J Connolly.;Jackie Bosch.;Olga Shestakovska.;Kelvin K H Ng.;Luciana Catanese.;Katalin Keltai.;Victor Aboyans.;Marco Alings.;Jong-Won Ha.;John Varigos.;Andrew Tonkin.;Martin O'Donnell.;Deepak L Bhatt.;Keith Fox.;Aldo Maggioni.;Scott D Berkowitz.;Nancy Cook Bruns.;Salim Yusuf.;John W Eikelboom.
来源: Circulation. 2019年139卷9期1134-1145页
Strokes were significantly reduced by the combination of rivaroxaban plus aspirin in comparison with aspirin in the COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies). We present detailed analyses of stroke by type, predictors, and antithrombotic effects in key subgroups.
786. Medication Discontinuation in the IMPROVE-IT Trial.
作者: Ann Marie Navar.;Matthew T Roe.;Jennifer A White.;Christopher P Cannon.;Yuliya Lokhnygina.;L Kristin Newby.;Robert P Giugliano.;Andrew M Tershakovec.;Eugene Braunwald.;Robert M Califf.;Michael A Blazing.
来源: Circ Cardiovasc Qual Outcomes. 2019年12卷1期e005041页
Although cholesterol-lowering medications can reduce the risk of recurrent cardiovascular events, premature discontinuation limits effectiveness. Discontinuation rates have not been systematically reported for lipid-lowering trials.
787. Platelet Inhibition With Cangrelor and Crushed Ticagrelor in Patients With ST-Segment-Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention.
作者: Francesco Franchi.;Fabiana Rollini.;Andrea Rivas.;Mustafa Wali.;Maryuri Briceno.;Malhar Agarwal.;Zubair Shaikh.;Ahmed Nawaz.;Gabriel Silva.;Latonya Been.;Ramez Smairat.;Marc Kaufman.;Andres M Pineda.;Siva Suryadevara.;Daniel Soffer.;Martin M Zenni.;Theodore A Bass.;Dominick J Angiolillo.
来源: Circulation. 2019年139卷14期1661-1670页
The platelet inhibitory effects induced by oral P2Y12 receptor antagonists are delayed in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention (P-PCI). In turn, this leads to a gap in platelet inhibition, exposing patients to an increased risk of early thrombotic complications and underscoring the need to define strategies associated with more effective platelet inhibition in the peri-primary percutaneous coronary intervention period. Cangrelor is an intravenous P2Y12 inhibitor with prompt and potent antiplatelet effects. However, to date, there are limited data on the effects of cangrelor used in combination with ticagrelor in patients undergoing primary percutaneous coronary intervention. Moreover, questions have emerged on the potential for drug-drug interactions during the transition from cangrelor to oral P2Y12 inhibitors.
788. Multicenter Study of the Validity of Additional Freeze Cycles for Cryoballoon Ablation in Patients With Paroxysmal Atrial Fibrillation: The AD-Balloon Study.
作者: Koji Miyamoto.;Atsushi Doi.;Kanae Hasegawa.;Yoshiaki Morita.;Tsuyoshi Mishima.;Ippei Suzuki.;Kenichi Kaseno.;Kenzaburo Nakajima.;Naoya Kataoka.;Tsukasa Kamakura.;Mitsuru Wada.;Kenichiro Yamagata.;Kohei Ishibashi.;Yuko Y Inoue.;Satoshi Nagase.;Takashi Noda.;Takeshi Aiba.;Masanori Asakura.;Chisato Izumi.;Teruo Noguchi.;Hiroshi Tada.;Masahiko Takagi.;Satoshi Yasuda.;Kengo F Kusano.
来源: Circ Arrhythm Electrophysiol. 2019年12卷1期e006989页
Pulmonary vein isolation (PVI) is a cornerstone of catheter ablation in patients with paroxysmal atrial fibrillation, and balloon-based ablation has been recently performed worldwide. The second-generation cryoballoon (CB2) ablation has proven to be highly effective in achieving freedom from paroxysmal atrial fibrillation. However, there are some debatable questions, including the ideal number of freeze cycles.
789. Sustainability of Blood Pressure Reduction in Black Barbershops.
作者: Ronald G Victor.;Ciantel A Blyler.;Ning Li.;Kathleen Lynch.;Norma B Moy.;Mohamad Rashid.;L Cindy Chang.;Joel Handler.;Jeffrey Brettler.;Florian Rader.;Robert M Elashoff.
来源: Circulation. 2019年139卷1期10-19页
We developed a new model of hypertension care for non-Hispanic black men that links health promotion by barbers to medication management by American Society of Hypertension-certified pharmacists and demonstrated efficacy in a 6-month cluster-randomized trial. The marked reduction in systolic blood pressure (BP) seen at 6 months warranted continuing the trial through 12 months to test sustainability, a necessary precondition for implementation research.
790. Empagliflozin Reduced Mortality and Hospitalization for Heart Failure Across the Spectrum of Cardiovascular Risk in the EMPA-REG OUTCOME Trial.
作者: David Fitchett.;Silvio E Inzucchi.;Christopher P Cannon.;Darren K McGuire.;Benjamin M Scirica.;Odd Erik Johansen.;Steven Sambevski.;Stefan Kaspers.;Egon Pfarr.;Jyothis T George.;Bernard Zinman.
来源: Circulation. 2019年139卷11期1384-1395页
In the EMPA-REG OUTCOME trial (BI 10773 [Empagliflozin] Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients) in patients with type 2 diabetes mellitus and atherosclerotic cardiovascular disease, in comparison with placebo, empagliflozin reduced the risks of 3-point major adverse cardiovascular events (3-point MACE), cardiovascular and all-cause death, and hospitalization for heart failure. We investigated whether these effects varied across the spectrum of baseline cardiovascular risk.
791. Angiotensin Receptor Neprilysin Inhibitor for Functional Mitral Regurgitation.
作者: Duk-Hyun Kang.;Sung-Ji Park.;Sung-Hee Shin.;Geu-Ru Hong.;Sahmin Lee.;Min-Seok Kim.;Sung-Cheol Yun.;Jong-Min Song.;Seung-Woo Park.;Jae-Joong Kim.
来源: Circulation. 2019年139卷11期1354-1365页
The morbidity and mortality of patients with functional mitral regurgitation (MR) remain high, but no pharmacological therapy has been proven effective. The hypothesis of this study was that sacubitril/valsartan would be superior to valsartan alone in improving functional MR via dual inhibition of the renin-angiotensin system and neprilysin.
792. Endovascular Thrombus Removal for Acute Iliofemoral Deep Vein Thrombosis.
作者: Anthony J Comerota.;Clive Kearon.;Chu-Shu Gu.;Jim A Julian.;Samuel Z Goldhaber.;Susan R Kahn.;Michael R Jaff.;Mahmood K Razavi.;Andrei L Kindzelski.;Riyaz Bashir.;Parag Patel.;Mel Sharafuddin.;Michael J Sichlau.;Wael E Saad.;Zakaria Assi.;Lawrence V Hofmann.;Margaret Kennedy.;Suresh Vedantham.; .
来源: Circulation. 2019年139卷9期1162-1173页
The ATTRACT trial (Acute Venous Thrombosis: Thrombus Removal with Adjunctive Catheter-Directed Thrombolysis) previously reported that pharmacomechanical catheter-directed thrombolysis (PCDT) did not prevent postthrombotic syndrome (PTS) in patients with acute proximal deep vein thrombosis. In the current analysis, we examine the effect of PCDT in ATTRACT patients with iliofemoral deep vein thrombosis.
793. Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
作者: Michelle L O'Donoghue.;Sergio Fazio.;Robert P Giugliano.;Erik S G Stroes.;Estella Kanevsky.;Ioanna Gouni-Berthold.;KyungAh Im.;Armando Lira Pineda.;Scott M Wasserman.;Richard Češka.;Marat V Ezhov.;J Wouter Jukema.;Henrik K Jensen.;S Lale Tokgözoğlu.;François Mach.;Kurt Huber.;Peter S Sever.;Anthony C Keech.;Terje R Pedersen.;Marc S Sabatine.
来源: Circulation. 2019年139卷12期1483-1492页
Lipoprotein(a) [Lp(a)] may play a causal role in atherosclerosis. PCSK9 (proprotein convertase subtilisin/kexin 9) inhibitors have been shown to significantly reduce plasma Lp(a) concentration. However, the relationship between Lp(a) levels, PCSK9 inhibition, and cardiovascular risk reduction remains undefined.
794. Prospective Validation of the Emergency Heart Failure Mortality Risk Grade for Acute Heart Failure.
作者: Douglas S Lee.;Jacques S Lee.;Michael J Schull.;Bjug Borgundvaag.;Marcia L Edmonds.;Maria Ivankovic.;Shelley L McLeod.;Jonathan F Dreyer.;Sam Sabbah.;Phillip D Levy.;Tara O'Neill.;Alice Chong.;Therese A Stukel.;Peter C Austin.;Jack V Tu.
来源: Circulation. 2019年139卷9期1146-1156页
Improved risk stratification of acute heart failure in the emergency department may inform physicians' decisions regarding patient admission or early discharge disposition. We aimed to validate the previously-derived Emergency Heart failure Mortality Risk Grade for 7-day (EHMRG7) and 30-day (EHMRG30-ST) mortality.
795. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk.
作者: Suzanne J Baron.;Kaijun Wang.;John A House.;Elizabeth A Magnuson.;Matthew R Reynolds.;Raj Makkar.;Howard C Herrmann.;Susheel Kodali.;Vinod H Thourani.;Samir Kapadia.;Lars Svensson.;Michael J Mack.;David L Brown.;Mark J Russo.;Craig R Smith.;John Webb.;Craig Miller.;Martin B Leon.;David J Cohen.
来源: Circulation. 2019年139卷7期877-888页
In patients with severe aortic stenosis (AS) at intermediate surgical risk, treatment with transcatheter aortic valve replacement (TAVR) or surgical aortic valve replacement (SAVR) results in similar rates of death or stroke at 2 years. Whether TAVR is cost-effective compared with SAVR for intermediate-risk patients remains uncertain.
796. A Phase 2 Randomized, Sham-Controlled Trial of Internal Carotid Artery Infusion of Autologous Bone Marrow-Derived ALD-401 Cells in Patients With Recent Stable Ischemic Stroke (RECOVER-Stroke).
作者: Sean I Savitz.;Dileep Yavagal.;George Rappard.;William Likosky.;Neal Rutledge.;Carmelo Graffagnino.;Yazan Alderazi.;Jennifer A Elder.;Peng R Chen.;Ronald F Budzik.;Ronald Tarrel.;David Y Huang.;James M Hinson.
来源: Circulation. 2019年139卷2期192-205页
Ischemic stroke has no approved treatments to enhance recovery. ALD-401 is an enriched population of aldehyde dehydrogenase-bright stem cells, capable of reducing neurological deficits in animal models. The primary objective of this trial was to determine the safety of internal carotid artery, intra-arterially delivered autologous bone marrow-derived ALD-401 in patients with disabling middle cerebral artery stroke in comparison with sham harvest with sham infusion. Secondary objectives were to determine feasibility and efficacy.
797. Glycemic Control, Cardiac Autoimmunity, and Long-Term Risk of Cardiovascular Disease in Type 1 Diabetes Mellitus.
作者: Giovane R Sousa.;David Pober.;Alfonso Galderisi.;HuiJuan Lv.;Liping Yu.;Alexandre C Pereira.;Alessandro Doria.;Mikhail Kosiborod.;Myra A Lipes.
来源: Circulation. 2019年139卷6期730-743页
Poor glycemic control is associated with increased risk of cardiovascular disease (CVD) in type 1 diabetes mellitus (T1DM); however, little is known about mechanisms specific to T1DM. In T1DM, myocardial injury can induce persistent cardiac autoimmunity. Chronic hyperglycemia causes myocardial injury, raising the possibility that hyperglycemia-induced cardiac autoimmunity could contribute to long-term CVD complications in T1DM.
798. Phase I/II Trial of Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia.
作者: Clifford G Robinson.;Pamela P Samson.;Kaitlin M S Moore.;Geoffrey D Hugo.;Nels Knutson.;Sasa Mutic.;S Murty Goddu.;Adam Lang.;Daniel H Cooper.;Mitchell Faddis.;Amit Noheria.;Timothy W Smith.;Pamela K Woodard.;Robert J Gropler.;Dennis E Hallahan.;Yoram Rudy.;Phillip S Cuculich.
来源: Circulation. 2019年139卷3期313-321页
Case studies have suggested the efficacy of catheter-free, electrophysiology-guided noninvasive cardiac radioablation for ventricular tachycardia (VT) using stereotactic body radiation therapy, although prospective data are lacking.
799. Whole-Genome Sequencing to Characterize Monogenic and Polygenic Contributions in Patients Hospitalized With Early-Onset Myocardial Infarction.
作者: Amit V Khera.;Mark Chaffin.;Seyedeh M Zekavat.;Ryan L Collins.;Carolina Roselli.;Pradeep Natarajan.;Judith H Lichtman.;Gail D'Onofrio.;Jennifer Mattera.;Rachel Dreyer.;John A Spertus.;Kent D Taylor.;Bruce M Psaty.;Stephen S Rich.;Wendy Post.;Namrata Gupta.;Stacey Gabriel.;Eric Lander.;Yii-Der Ida Chen.;Michael E Talkowski.;Jerome I Rotter.;Harlan M Krumholz.;Sekar Kathiresan.
来源: Circulation. 2019年139卷13期1593-1602页
The relative prevalence and clinical importance of monogenic mutations related to familial hypercholesterolemia and of high polygenic score (cumulative impact of many common variants) pathways for early-onset myocardial infarction remain uncertain. Whole-genome sequencing enables simultaneous ascertainment of both monogenic mutations and polygenic score for each individual.
800. Myocardial and Systemic Inflammation in Acute Stress-Induced (Takotsubo) Cardiomyopathy.
作者: Caroline Scally.;Hassan Abbas.;Trevor Ahearn.;Janaki Srinivasan.;Alice Mezincescu.;Amelia Rudd.;Nicholas Spath.;Alim Yucel-Finn.;Raif Yuecel.;Keith Oldroyd.;Ciprian Dospinescu.;Graham Horgan.;Paul Broadhurst.;Anke Henning.;David E Newby.;Scott Semple.;Heather M Wilson.;Dana K Dawson.
来源: Circulation. 2019年139卷13期1581-1592页
Acute stress-induced (takotsubo) cardiomyopathy can result in a heart failure phenotype with a prognosis comparable with that of myocardial infarction. In this study, we hypothesized that inflammation is central to the pathophysiology and natural history of takotsubo cardiomyopathy.
|